comparemela.com

Latest Breaking News On - அதிகமானது வளைகுடா பரப்பளவு தாயகம் வளர்ச்சி நிதி - Page 3 : comparemela.com

ConsenSys raises $65M from JP Morgan, Mastercard, UBS to build infrastructure for DeFi

ConsenSys, a key player in crypto and a major proponent of the Ethereum blockchain, has raised a $65 million funding round from J.P. Morgan, Mastercard, and UBS AG, as well as major blockchain companies Protocol Labs, the Maker Foundation, Fenbushi, The LAO and Alameda Research. Additional investors include CMT Digital and the Greater Bay Area Homeland Development Fund. The fundraise looks like a highly strategic one, based around the idea that traditional institutions will need visibility into the increasingly influential world of ‘decentralized finance’ (DeFi) and the Web3 applications being developed on the Ethereum blockchain.

J P Morgan Chase & Co (JPM), Mastercard (MA), UBS Ag (UBS) - Why JPMorgan, UBS, Mastercard Invested $65M In Ethereum Infrastructure Company ConsenSys

J P Morgan Chase & Co (JPM), Mastercard (MA), UBS Ag (UBS) - Why JPMorgan, UBS, Mastercard Invested $65M In Ethereum Infrastructure Company ConsenSys
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

China Tech Digest: DJI Launches Intelligent Driving Business; Alibaba Talks About Scrutiny

DJI launches its intelligent driving business brand "DJI Auto" Chinese consumer drone maker DJI today officially launched its intelligent driving business . Alibaba, Artificial Intelligence, DJI, Hillhouse Capital Group, Horizon Robotics, Tencent, Tencent Music, tesla, Today

Carlyle, Warburg Pincus co-lead $123m round in Shanghai biopharma firm Abbisko

Carlyle leads $123m round in Shanghai-based biopharma firm Abbisko Premium Abbisko Therapeutics, a Shanghai-based biopharmaceutical firm, announced on Friday the completion of a Series D funding round at $123 million to advance the startup’s clinical programmes and to expand its portfolio in the discovery and preclinical development stages. Continue reading this story with a subscription to DealStreetAsia. Contact us for corporate subscriptions at subs@dealstreetasia.com. Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday REGISTER stories left placeholder You have one free story left this month. You have stories left placeholder free stories left this month.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.